Precision-tuning brain receptor function for next-generation neurological therapies

Modulate Bio is pioneering next-generation GABAA-R modulators for the treatment of Essential Tremor, epilepsy and anxiety. Their platform enables precise control of GABAA-R activation by screening compounds across all physiologically relevant GABA concentrations. Founded in Professor Kevin Hodgetts’ Laboratory for Drug Discovery in Neuroscience at the Brigham and Women’s Hospital, the company is guided by Dr. Hodgetts and Dr. Dario Doller, an industry veteran with 30+ years of drug discovery leadership. Modulate Bio’s allosteric modulation approach enables the development of novel GABAA small molecules that overcome the side effect limitations of existing therapies.